Skip to main content
Funded Studies

Richard Gordon

Group Leader, Clinical Neuroscience at The University of Queensland

Location: Brisbane QLD Australia

Dr. Richard Gordon leads the Translational Neuroscience Laboratory at The University of Queensland in Brisbane, Australia. His research program aims at understanding how chronic inflammation and microbiome dysfunction are initiated in Parkinson’s disease (PD) and how they contribute to disease progression. His group works on identifying new therapeutic targets and treatment strategies to slow or halt the progression of PD. Dr. Gordon’s research has contributed to groundbreaking advances in his field, including most recently, the discovery of inflammasome activation in PD as a driver of synuclein pathology and disease progression. His team is also studying inflammasome activation pathways as biomarkers for PD. Dr. Gordon is a certified toxicologist with the American Board of Toxicology (ABT) and has served as a member of the Gene Technology Technical Advisory Committee for the Australian Federal Government. He is also a Science Ambassador for the World Parkinson Coalition.


Associated Grants

  • Exploring How a Chemical Produced by Intestinal Microbes Contributes to the Pathology and Progression of Parkinson's Disease

    2021


  • Development of an Anti-inflammatory Drug for the Treatment of Parkinson’s Disease

    2021


  • Targeting the Body’s Circadian Clock to Improve Sleep Quality in Parkinson’s Disease

    2021


  • Pharmacological Targeting of Inflammasome Activation Mechanisms in Synuclein Models of Parkinson's Disease

    2019


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.